|
|
|
|
| LEADER |
03846nam a22003613i 4500 |
| 001 |
90704d71-5eed-4b0f-8a79-2a4f659202de |
| 005 |
20240901000000.0 |
| 008 |
220628s2021 xx o ||||0 eng d |
| 020 |
|
|
|a 9781683733508
|q (electronic bk.)
|
| 020 |
|
|
|z 9781683732983
|
| 035 |
|
|
|a (Au-PeEL)EBL6741027
|
| 035 |
|
|
|a (MiAaPQ)EBC6741027
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 100 |
1 |
|
|a Wegmann, Joseph
|
| 245 |
1 |
0 |
|a Psychopharmacology :
|b Straight Talk on Mental Health Medications, 4th Edition
|
| 250 |
|
|
|a 4th ed
|
| 264 |
|
1 |
|a Eau Claire, WI :
|b PESI,
|c 2021
|
| 264 |
|
4 |
|c ©2021
|
| 300 |
|
|
|a 1 online resource (335 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Cover -- Copyright -- The Author -- Table of Contents -- Acknowledgments -- Introduction: Whats Inside -- Section One: Getting Started with The Client -- Chapter 1: The DSM® -- Medical Model -- Neurobiology -- Chapter 2: The First Visits with the Client -- Section Two: Clinical Syndromes -- Chapter 3: Schizophrenia and Other Psychotic Spectrum Disorders -- Chapter 4: Depression -- Chapter 5: Bipolar Disorder -- Chapter 6: The Many Manifestations of Anxiety -- Chapter 7: Opiates, Opioids and Medical Marijuana -- Section Three: Treatment -- Chapter 8: Antipsychotics -- Dosage Range Chart-Antipsychotic Medications -- Chapter 9: Antidepressants: -- Dosage Range Chart-Antidepressants -- Chapter 10: Treatment-Resistant Depression -- Chapter 11: Other Treatment Paths for Managing Depression -- Chapter 12: Mood-Stabilizing Agents -- Dosage Range Chart-Mood Stabilizers, Anticonvulsants -- Chapter 13: Antianxiety Medications, Sleep Agents -- Dosage Range Chart-Antianxiety Medications, Sleep Agents -- Chapter 14: Anxiety and Insomnia: Treatment Beyond Medication -- Chapter 15: Treatment of Opiate and Opioid Disorders -- Chapter 16: Chronic Pain Management -- Section Four: Specific Populations, ADHD, Herbals amp -- Supplements, Solving Medication Challenges -- Chapter 17: Specific Population Groups -- Chapter 18: Attention Deficit Hyperactivity Disorder -- Dosage Range Chart-Antianxiety Medications, Sleep Agents -- Chapter 19: Herbals and Supplements -- Chapter 20: Solving Medication Challenges -- Chapter 21: Psychopharmacology Going Forward -- Conclusion -- Appendices -- Appendix I: Making a Medication Referral -- Appendix II: Frequently Asked Questions -- Appendix III: Medication Noncompliance and How Healthcare Professionals Can Help -- Appendix IV: Are All Drugs Created Equal? Brand Name vs. Generic Medications -- Appendix V: The Placebo Effect
|
| 505 |
8 |
|
|a Appendix VI: Tapering and Discontinuing Psychotropic Medication -- Appendix VII: Pharmacogenetic Testing in Psychiatry -- Appendix VIII: Talking to Clients About Psychotropic Medication Side Effects -- Appendix IX: Tele-Treatment -- Appendix X: Master Drug Chart -- References -- Resource Websites -- Index
|
| 506 |
|
|
|a Access restricted by licensing agreement
|
| 520 |
|
|
|a Author Joe Wegmann draws on over three decades of clinical experience in psychopharmacology and psychotherapy, to provide his unique perspective on psychotropic medication management
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources
|
| 590 |
|
|
|a Access is available to the Yale community
|
| 730 |
0 |
|
|a ProQuest ebook central
|
| 776 |
0 |
8 |
|i Print version:
|a Wegmann, Joseph
|t Psychopharmacology
|d Eau Claire, WI : PESI,c2021
|z 9781683732983
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 999 |
1 |
0 |
|i 90704d71-5eed-4b0f-8a79-2a4f659202de
|l 16283481
|s US-CTY
|m psychopharmacologystraight_talk_on_mental_health_medications_4th_editi_____2021____4__pesi_a________________________________________wegmann__joseph____________________e
|
| 999 |
1 |
1 |
|l 16283481
|s ISIL:US-CTY
|t BKS
|a yulint
|c None
|p UNLOANABLE
|